Ibandronic Acid Stada

Ibandronic Acid, the active ingredient in Ibandronic Acid Stada, is a bisphosphonate presented as a intravenous solution for intravenous use. It treats osteoporosis and Paget's disease of bone in adult patients. GNH USA supplies Ibandronic Acid Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibandronic Acid is a bisphosphonate used to manage disorders of bone remodeling. - Osteoporosis: reduces the risk of vertebral, hip and other fractures in post‑menopausal women and men. - Paget's disease of bone: normalises abnormal bone turnover and alleviates bone pain. - High‑risk fracture patients: further lowers the incidence of new fractures after a prior osteoporotic fracture.

Adverse reactions may occur with intravenous bisphosphonate therapy.

Common Side Effects: - Acute‑phase reaction (fever, myalgia, arthralgia) - Flu‑like symptoms - Nausea or vomiting - Injection‑site pain or erythema

Serious or Rare Side Effects: - Osteonecrosis of the jaw - Atypical femur fracture - Severe hypocalcaemia - Acute renal failure or worsening of pre‑existing renal impairment - Anaphylactic or severe hypersensitivity reactions - Cardiac arrhythmias (rare)

Prior assessment and monitoring are essential when using Ibandronic Acid. - Renal function: evaluate creatinine clearance before each infusion. - Calcium status: correct hypocalcaemia and ensure adequate vitamin D levels. - Pregnancy: avoid use unless the potential benefit justifies the risk to the fetus. - Concomitant bisphosphonates: do not administer overlapping bisphosphonate therapy. - Nephrotoxic agents: avoid simultaneous use of other drugs that may impair kidney function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ibandronic Acid may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Other bisphosphonates: risk of excessive suppression of bone turnover. - Aminoglycoside antibiotics (e.g., gentamicin): heightened nephrotoxicity. - NSAIDs in patients with renal impairment: increased risk of renal adverse events.

Moderate Interactions (Monitor Closely): - Calcium, magnesium or multivitamin supplements taken within 30 minutes of infusion: may reduce drug efficacy. - Vitamin D analogues: monitor serum calcium and adjust supplementation as needed.